journal article·2014-06-24Open access

Combinatorial Photothermal and Immuno Cancer Therapy Using Chitosan-Coated Hollow Copper Sulfide Nanoparticles

Liangran Guo, Daisy D. Yan, Dongfang Yang, Yajuan Li, Xiaodong Wang, Olivia Zalewski, Bingfang Yan, Wei Lu

ACS Nano· Volume 8· Issue 6

Abstract

Near-infrared light-responsive inorganic nanoparticles have been shown to enhance the efficacy of cancer photothermal ablation therapy. However, current nanoparticle-mediated photothermal ablation is more effective in treating local cancer at the primary site than metastatic cancer. Here, we report the design of a near-infrared light-induced transformative nanoparticle platform that combines photothermal ablation with immunotherapy. The design is based on chitosan-coated hollow CuS nanoparticles that assemble the immunoadjuvants oligodeoxynucleotides containing the cytosine-guanine (CpG) motifs. Interestingly, these structures break down after laser excitation, reassemble, and transform into polymer complexes that improve tumor retention of the immunotherapy. In this "photothermal immunotherapy" approach, photothermal ablation-induced tumor cell death reduces tumor growth and releases tumor antigens into the surrounding milieu, while the immunoadjuvants potentiate host antitumor immunity. Our results indicated that combined photothermal immunotherapy is more effective than either immunotherapy or photothermal therapy alone against primary treated and distant untreated tumors in a mouse breast cancer model. These hollow CuS nanoparticles are biodegradable and can be eliminated from the body after laser excitation.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Nanoplatforms for cancer theranostics · Extracellular vesicles in disease · Gold and Silver Nanoparticles Synthesis and Applications

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Biomedical and Pharmaceutical Sciences, College of Pharmacy, The University of Rhode Island, Kingston, Rhode Island 02881, United States

School of Pharmacy, Fudan University, Shanghai 201203, China

Funding

National institute of Health and Medical Research

References (55)

Show source-provided references
1. Paiva M. B. · Lasers Surg. Med. · 2002 · 31 · 6410.1002/lsm.10077 ↗
2. Paiva M. B. · Laryngoscope · 1998 · 108 · 127710.1097/00005537-199809000-00003 ↗
3. Hirsch L. R. · Proc. Natl. Acad. Sci. U.S.A. · 2003 · 100 · 1354910.1073/pnas.2232479100 ↗
4. Dickerson E. B. · Cancer Lett. · 2008 · 269 · 5710.1016/j.canlet.2008.04.026 ↗
5. Chen J. · Small · 2010 · 6 · 81110.1002/smll.200902216 ↗
6. Skrabalak S. E. · Adv. Mater. · 2007 · 19 · 317710.1002/adma.200701972 ↗
7. Lu W. · Clin. Cancer Res. · 2009 · 15 · 87610.1158/1078-0432.CCR-08-1480 ↗
8. Kam N. W. · Proc. Natl. Acad. Sci. U.S.A. · 2005 · 102 · 1160010.1073/pnas.0502680102 ↗
9. Li Y. · Nanomedicine · 2010 · 5 · 116110.2217/nnm.10.85 ↗
10. Song S. · J. Nucl. Med. · 2011 · 52 · 79210.2967/jnumed.110.086116 ↗
11. Tian Q. · ACS Nano · 2011 · 5 · 976110.1021/nn203293t ↗
12. Tian Q. · Adv. Mater. · 2011 · 23 · 354210.1002/adma.201101295 ↗
13. Zhou M. · J. Am. Chem. Soc. · 2010 · 132 · 1535110.1021/ja106855m ↗
14. Pilot Study of Aurolase(Tm) Therapy in Refractory and/or Recurrent Tumors of the Head and Neck;http://clinicaltrials.gov/show/NCT00848042.
15. Efficacy Study of Aurolase Therapy in Subjects with Primary and/or Metastatic Lung Tumors;http://clinicaltrials.gov/show/NCT01679470.
16. Chen W. R. · Cancer Res. · 2001 · 61 · 459
17. Naylor M. F. · Br. J. Dermatol. · 2006 · 155 · 128710.1111/j.1365-2133.2006.07514.x ↗
18. Hodge J. W. · Oncology · 2008 · 22 · 1064
19. Krieg A. M. · Nat. Rev. Drug Discovery · 2006 · 5 · 47110.1038/nrd2059 ↗
20. Iwasaki A. · Nat. Immunol. · 2004 · 5 · 98710.1038/ni1112 ↗
21. Vollmer J. · Adv. Drug Delivery Rev. · 2009 · 61 · 19510.1016/j.addr.2008.12.008 ↗
22. Bode C. · Expert Rev. Vaccines · 2011 · 10 · 49910.1586/erv.10.174 ↗
23. Krieg A. M. · Oncogene · 2008 · 27 · 16110.1038/sj.onc.1210911 ↗
24. Murad Y. M. · BioDrugs · 2009 · 23 · 36110.2165/11316930-000000000-00000 ↗
25. Wilson K. D. · Adv. Drug Delivery Rev. · 2009 · 61 · 23310.1016/j.addr.2008.12.014 ↗
26. Bourquin C. · J. Immunol. · 2008 · 181 · 299010.4049/jimmunol.181.5.2990 ↗
27. Chikh G. · Int. Immunol. · 2009 · 21 · 75710.1093/intimm/dxp044 ↗
28. de Jong S. D. · J. Immunol. · 2010 · 184 · 609210.4049/jimmunol.0802442 ↗
29. Malyala P. · Adv. Drug Delivery Rev. · 2009 · 61 · 21810.1016/j.addr.2008.12.009 ↗
30. Schreiber H. A. · J. Immunol. Methods · 2010 · 356 · 4710.1016/j.jim.2010.02.009 ↗
31. Zhao D. · Clin. Cancer Res. · 2010 · 17 · 77110.1158/1078-0432.CCR-10-2444 ↗
32. Fan H. · Clin. Cancer Res. · 2012 · 18 · 562810.1158/1078-0432.CCR-12-1911 ↗
33. Kim J. H. · Angew. Chem., Int. Ed. · 2012 · 51 · 967010.1002/anie.201204989 ↗
34. Lin A. Y. · PLoS One · 2013 · 8 · e6355010.1371/journal.pone.0063550 ↗
35. Wei M. · Angew. Chem., Int. Ed. · 2012 · 51 · 120210.1002/anie.201105187 ↗
36. Guo L. · ACS Nano · 2013 · 7 · 878010.1021/nn403202w ↗
37. Takahashi H. · Chem. Commun. · 2005 · 224710.1039/b500337g ↗
38. Chen C. C. · J. Am. Chem. Soc. · 2006 · 128 · 370910.1021/ja0570180 ↗
39. Lu W. · Cancer Res. · 2010 · 70 · 317710.1158/0008-5472.CAN-09-3379 ↗
40. Wheeler D. A. · J. Phys. Chem. C · 2010 · 114 · 1812610.1021/jp1076824 ↗
41. Zhu H. · Inorg. Chem. · 2009 · 48 · 709910.1021/ic900201p ↗
42. Kim J. S. · Rapid Commun. Mass Spectrom. · 2001 · 15 · 229610.1002/rcm.509 ↗
43. Liu C. · J. Clin. Invest. · 2008 · 118 · 1165
44. Sasai M. · Science · 2010 · 329 · 153010.1126/science.1187029 ↗
45. Kortylewski M. · Nat. Biotechnol. · 2009 · 27 · 92510.1038/nbt.1564 ↗
46. Bae S. M. · Cancer Sci. · 2007 · 98 · 74710.1111/j.1349-7006.2007.00447.x ↗
47. 10.1002/jbio.20130007210.1002/jbio.201300072 ↗
48. Milas L. · Cancer Res. · 2004 · 64 · 507410.1158/0008-5472.CAN-04-0926 ↗
49. Mason K. A. · Radiother. Oncol. · 2006 · 80 · 19210.1016/j.radonc.2006.07.024 ↗
50. Mason K. A. · Front. Oncol. · 2012 · 2 · 10110.3389/fonc.2012.00101 ↗
51. Copier J. · Int. Rev. Immunol. · 2006 · 25 · 29710.1080/08830180600992472 ↗
52. Ramadan S. · Small · 2012 · 8 · 314310.1002/smll.201200783 ↗
53. Lee D. · Pharm. Res. · 2007 · 24 · 15710.1007/s11095-006-9136-9 ↗
54. Pouyanfard S. · PLoS One · 2012 · 7 · e4953910.1371/journal.pone.0049539 ↗
55. Ejrnaes M. · J. Immunol. · 2005 · 174 · 274610.4049/jimmunol.174.5.2746 ↗